“MagQu” Phospho-α-Synuclein(pS129) IMR Reagent
- Catalog No. MF-PS1-0060
- For rapid quantifying Phospho-α-synuclein(pS129) by Immuno Magnetic Reduction (IMR).
- Quantifying Phospho-α-synuclein(pS129) in the sample easily, rapidly, and accurately
- Magnetic Nanoparticle
- Dextran layer
- For Parkinson’s disease (PD) research and for in-vitro diagnosis use
Parkinson’s disease (PD) is characterized by the intraneuronal α-synuclein inclusions called Lewy bodies. Increase of phosphorylation of α-synuclein in Serine 129 (S129) has been correlated with the aggregation, toxicity, protein interaction and turnover of α-synuclein. Thus, S129 can indicate the pathogenesis of PD.1,2
The “MagQu” Phospho-α-synuclein IMR Reagent is designed for rapid quantifying phosphorylated α-synuclein (S129) by ImmunoMagnetic Reduction (IMR). We conjugate antibody on the surface of around 50 nm-in-diameter Fe3O4 magnetic particles. When the antibodies on the surface bind with phosphorylated α-synuclein (S129), the magnetic particles form clusters. Therefore, the ac susceptibility (Xac) of magnetic particles would be reduced in the adding ac magnetic field. By measuring the reduction of Xac, phosphorylated α-synuclein (S129) can be easily, rapidly and accurately quantified.
- Wang, Y., Shi, M., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M., Siderowf, A. D., Hurtig, H., Litvan, I., Schiess, M. C., Peskind, E. R., Masuda, M., Hasegawa, M., Lin, X., Pan, C., Galasko, D., Goldstein, D. S., Jensen, P. H., Yang, H., Cain, K. C., Zhang, J. (2012). Phosphorylated α-synuclein in Parkinson's disease. Science translational medicine, 4(121), 121ra20.
- Oueslati A. (2016). Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?. Journal of Parkinson's disease, 6(1), 39-51.
|Catalog Number||Description||Package Size|
|MF-PS1-0060||65 tests||1 mL x 4|
- Applications Content:Quantitative detection for ultra-low-concentration bio-molecules, e.g. Parkinson’s disease bio-markers in blood.